[go: up one dir, main page]

US20090123559A1 - Medicine to Treat Drug Addiction and Preparation Method Thereof - Google Patents

Medicine to Treat Drug Addiction and Preparation Method Thereof Download PDF

Info

Publication number
US20090123559A1
US20090123559A1 US11/989,520 US98952006A US2009123559A1 US 20090123559 A1 US20090123559 A1 US 20090123559A1 US 98952006 A US98952006 A US 98952006A US 2009123559 A1 US2009123559 A1 US 2009123559A1
Authority
US
United States
Prior art keywords
extract
radix
weight
parts
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/989,520
Other languages
English (en)
Inventor
Zheng Yang
Ming Fan
Jijun Chen
Guozhang Jin
Wuxian Ren
Wei Feng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Basic Medical Sciences of AMMS
Yabao Pharmaceutical Group Corp
Original Assignee
Shanxi Yabao Pharmaceutical Group Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanxi Yabao Pharmaceutical Group Corp filed Critical Shanxi Yabao Pharmaceutical Group Corp
Assigned to SHANXI YABAO PHARMACEUTICAL GROUP CORP., INSTITUTE OF BASIC MEDICAL SCIENCES, ACADEMY OF MILITARY MEDICAL SCIENCES reassignment SHANXI YABAO PHARMACEUTICAL GROUP CORP. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHEN, JIJUN, FAN, MING, FENG, Wei, JIN, GUOZHANG, REN, WUXIAN, YANG, ZHENG
Publication of US20090123559A1 publication Critical patent/US20090123559A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8968—Ophiopogon (Lilyturf)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a pharmaceutical extract, composition and its preparation method and quality control method, especially relates to a pharmaceutical extract, composition that has effect to treat drug addiction, and its preparation method and quality control method.
  • patent CN1537549A and CN1537550A the declarer developed the traditional Chinese medicine compound prescription preparation which is prepared by five traditional Chinese medicine extracts of Radix Ginseng, Radix Astragali, Rhizoma Corydalis, Radix Angelicae Sinensis, Radix Ophiopogonis.
  • extract medicines by classification extract Radix Ginseng and Radix Angelicae Sinensis by ethanol reflux extraction process; extract effective ingredients of Radix Astragali and Radix Ophiopogonis by water-extraction and ethanol-precipitation process respectively; gain effective ingredients, effective alkaloids, from Rhizoma Corydalis by diafiltration with the acid solution, then basification and ethanol recrystallization.
  • These extracts compose the traditional Chinese medicine compound prescription preparation, which has preferable curative effect to treat stimulant withdrawal symptom and treat protracted withdrawal symptom of opioids addiction.
  • Rhizoma Corydalis which tetrahydropalmatine extracted from is raceme dl-THP, and it must further split racemes to get L-THP.
  • the content of raceme dl-THP contained in Rhizoma Corydalis is rather low, moreover, dosage of Rhizoma Corydalis in this drug addiction treatment prescription is large, Rhizoma Corydalis mainly depends on the artificial cultivation, its output is low, its cost is high, and it cannot meet the need of industrialization large production.
  • the purpose of the present invention is to provide a pharmaceutical extract which has effect to treat drug addiction; another purpose of the present invention is to provide a pharmaceutical composition which has effect to treat drug addiction; the third purpose of the present invention is to provide the preparation method and quality control method of this composition.
  • Total alkaloids of Radix Stephaniae Epigaeae the total alkaloids are produced by the following methods:
  • Pulverize Radix Stephaniae Epigaeae to coarse power add 35-100% ethanol at 4-10 times amount of stating material's, extract by reflux extraction from one to four times, 1-3 hours each time, filter, combine the filtrates of ethanol extract, recover ethanol, then concentrate to obtain the thick extract with relative density of 1.18-1.30 at 80° C.; acidify this thick extract until the pH value up to 1-4 by 3-18% HCl solution, filter, basify the filtrate until the pH value up to 8-11 by 8-20% NaOH solution, stand, collect the precipitate, wash the precipitate with water by filter, take the precipitate, dry it, then obtain total alkaloids of Radix Stephaniae Epigaeae.
  • Preferable preparation method of total alkaloids of Radix Stephaniae Epigaeae is as follows:
  • Pulverize Radix Stephaniae Epigaeae to coarse power add ethanol at 5 times amount of stating material's, extract by reflux extraction twice, 2 hours each time, filter, combine the filtrates of ethanol extract, recover ethanol, then concentrate to obtain the thick extract with relative density of 1.18-1.30 at 80° C.; acidify this thick extract until the pH value up to 2-3 by 5% HCl solution, filter, basify the filtrate until the pH value up to 9-10 by 10% NaOH solution, stand, collect the precipitate, wash the precipitate with water by filter, take the precipitate, dry it, then obtain total alkaloids from Radix Stephaniae Epigaeae.
  • the present invention declares a pharmaceutical composition that has effect to treat drug addiction, and starting material of this traditional Chinese medicine composition is composed of as follows:
  • the said starting material is composed of:
  • starting material of this invention pharmaceutical composition is produced to clinic or pharmaceutical acceptable dosage forms, for example: tablet, capsule, soft capsule, drop pill, pill, granule, honey refined extract, sustained-release preparation, rapid-release preparation, controlled-release preparation, oral liquid or injection.
  • This invention provides a preparation method of the said pharmaceutical composition preparation:
  • a preparation method of the pharmaceutical composition preparation is:
  • the present invention also provides starting material of a pharmaceutical composition is composed of as follows:
  • the said starting material is composed of:
  • Ginsenoside content in the said ethanol extract of Radix Ginseng is not less than 50 g/Kg; angelica lactone content in the ethanol extract of Radix Angelicae Sinensis is not less than 2 g/Kg; ( ⁇ ) tetrahydropalmatine content in the total alkaloids of Radix Stephaniae Epigaeae is not less than 20%; astragaloside content in the water extract of Radix Astragali is not less than 0.2 g/Kg; ophiopogonin content in the water extract of Radix Ophiopogonis is not less than 0.9 g/Kg.
  • Radix Ginseng in starting material of the said invention pharmaceutical composition can replace with equal weight parts Radix Panacis Quinquefolii, and ethanol extract of Radix Ginseng can replace with extract of Radix Panacis Quinquefolii.
  • Radix Stephaniae Epigaeae in the said invention pharmaceutical composition preferably chooses Stephania delavayi Diels from Mentspermaceae.
  • Quality control method of this invention pharmaceutical composition preparation include following identification and/or content determination.
  • Identification include one of or several following methods:
  • the upper layer solution is a mixture of n-butyl alcohol, ethyl acetate and water (4:1:5), according to ratio 10:1, a mix solution of this upper layer solution and methanol is used as developer, in developing, the development chamber is saturated by ammonia for 30 minutes, and developed distance is more than 15 cm, the plate was removed and air dried, and sprayed with ethanol solution of 10% sulfuric acid, then heated in 105° C. until visualize the chromatogram, the chromatogram produced by the test sample solution showed the same color spots as that displayed by the two reference substance solutions in their respectively corresponding areas;
  • Tetrahydropalmatine regarded as Radix Stephaniae Epigaeae is not less than 20 mg in each of 0.35-0.45 g capsule, pill, tablet, granule, honey refined extract, sustained-release preparation or rapid-release preparation of the said pharmaceutical composition.
  • the extract efficiency of extracting THPBs and L-THP from Radix Stephaniae Epigaeae in the present invention is rather high, and it reduces processes of extracting raceme tetrahydropalmatine dl-THP from Rhizoma Corydalis and further split raceme to gain L-THP.
  • Raceme dl-THP content in Rhizoma Corydalis is rather low, on the other hand, and tetrahydropalmatine is effective analgesia ingredient in the traditional Chinese medicine, Rhizoma Corydalis (Corydalis ambigua Cham.et Sch), but its practice content is very low.
  • Alkaloid extract efficiency of Caulis Fibraureae (Fibraurea recisa Pierre) is up to 6%, and it can be transformed to raceme tetrahydropalmatine through deoxidize reaction, but effective analgesia ingredient is ( ⁇ )tetrahydropalmatine, and it must further split raceme to gain L-THP, and there is no Stepholidine.
  • Radix Stephaniae Epigaeae is from Stephania delavayi Diels from Mentspermaceae, in which can extract alkaloid 3-4%, main ingredients in it is ( ⁇ )-tetrahydropalmatine, ( ⁇ ) stepholidine and ( ⁇ ) corydalmine and so on have the most distinctive pharmacological effect.
  • the said inventive extract technic for total alkaloids of Radix Stephaniae Epigaeae is simple, stable, easy control. Gain efficiency of THPBs is high, so it reduces cost of pharmaceutical manufacture.
  • the said inventive total alkaloids of Radix Stephaniae Epigaeae has drug abstain effect, can mostly raise expression of Penk mRNA or expression of POMC mRNA in arcuate nucleus.
  • the examination test ifies that combinations between Radix Stephaniae Epigaeae and the said invention composition, or total alkaloids of Radix Stephaniae Epigaeae and the said invention extract composition have synergistic effect, and this synergistic effect reduces side effects induced by only using total alkaloids of Radix Stephaniae Epigaeae with more prominent therapeutic effect.
  • the examination also testifies that this invention composition has more prominent curative effect than composition prescription (Guiyuan Tablet) containing Rhizoma Corydalis.
  • Synergistic effect of this invention pharmaceutical composition mainly indicates: block gain and expression of mouse morphine behavioral sensitization, inhibit formation and expression of morphine behavioral sensitization, prevent formation of morphine addicted behavior, inhibit sensitization behavior induced by morphine; reduce mouse's activity, inhibit acute high activity effect of methyl benzedrine; also block gain and expression of mouse methyl benzedrine behavioral sensitization.
  • this invention pharmaceutical composition preparation is proved that it has drug abstinence, alleviates symptom, psychology craving inhibition, relapse reducing effects for dependence or addiction inducing by opioids substances, including heroin, morphine, pethidne, methadone, and so on, as well as other spiritual active materials (including cocaine, benzedrines stimulant, wine, smoke, cannabis, sedatives and hypnotics, and so on).
  • opioids substances including heroin, morphine, pethidne, methadone, and so on
  • other spiritual active materials including cocaine, benzedrines stimulant, wine, smoke, cannabis, sedatives and hypnotics, and so on.
  • the present invention indicates that Stephania delavayi Diels from Mentspermaceae has prominent effect in medicines to treat drug addiction.
  • Extract for THPBs effective total alkaloids of Radix Stephaniae Epigaeae, air dry and pulverize Radix Stephaniae Epigaeae to get 300 g starting material powder, reflux with 85% ethanol for three times, add 1500 mL ethanol each time, reflux for 1 hour to gain tetrahydroprotoberberines (THPBs) alkaloid solution extracted from Radix Stephaniae Epigaeae, then recover ethanol and concentrate to obtain the thick extract 100 ml with relative density of 0.905 at 80° C.
  • THPBs tetrahydroprotoberberines
  • UV-spectrophotometer instrument: Shimazu 210A UV-spectrophotometer. Solvent is ethanol, and determination data of UV map: Uv ⁇ max MeOH (Iog ⁇ ) nm: 210 (4.46), 219 (sh, 4.23), 281 (3.72). Analysis: B strap of aromatic ring at 210 nm, K strap of aromatic ring at 219 nm, characteristic absorption signal at 281 nm.
  • 13 C nuclear magnetic resonance spectra 13 C NMR: instrument: Bruker DRX-500 superconductor nuclear magnetic resonance spectrometer. Determination condition: solvent is C 5 D 5 N, and internal standard is TMS, determining at 125 MHz frequency.
  • 13 C NMR of this compound provides 21 carbon atom signals, and you can further identify characters of each carbon atom by combining with 13 C NMR DEPT spectrum, corresponding to ( ⁇ )-tetrahydropalmatine.
  • the physical properties, melting point and optical value of this compound are corresponding to ( ⁇ )-tetrahydropalmatine.
  • this compound structure is ( ⁇ )-tetrahydropalmatine, english name: ( ⁇ )-tetrahydropalmatine, molecular formula: C 21 H 25 NO 4 , molecular weight: 355.4275.
  • Sample preparation accurately take 0.00201 g prepared ( ⁇ ) tetrahydropalmatine, add solvent until volume up to 2.0 mL in volumetric flask, its concentration is 1.05 mg/mL.
  • Chromatograph condition instrument: Waters 2996, (US), diode array detector; chromatographic column: Waters ODS2 (3.9 ⁇ 150 Mm, 5 ⁇ m).
  • Mobile phase acetonitrile-water (40:60), flow rate: 1 mL/min; detection wavelength: 225 nm, column temperature: 35° C., injection volume: 30 ⁇ l.
  • Single factor variance analysis indicates: grade of total alkaloids of Radix Stephaniae Epigaeae group is lower than the placebo group. There is difference between grade of day 7 after administration and grade of day 5, day 14 after drug withdrawal (P ⁇ 0.05)
  • Single factor variance analysis indicates: there is no significant difference in every group at admission day, at day7, day21, day28 after administration, at day5, day14 after drug withdrawal; there is significant difference (P ⁇ 0.05) between in every group at day14 after administration and day5 after drug withdrawal.
  • Penk mRNA expression of dependence group decrease significantly (P ⁇ 0.05).
  • total alkaloids of Radix Stephaniae Epigaeae group (obtain in experiment 2) except has no significantly increasing Penk mRNA expression in CPu, has significantly increasing Penk mRNA expression in all other detected sites (P ⁇ 0.05).
  • total alkaloids of Radix Stephaniae Epigaeae group has significantly increasing Penk mRNA expression in all detected sites (P ⁇ 0.05).
  • Penk mRNA expression is same to normal saline group, all of them are less than normal control group
  • Penk mRNA expression of total alkaloids of Radix Stephaniae Epigaeae group (obtain in experiment 2) significantly increase, and there is significant different compared with normal saline group (P ⁇ 0.05); but there is no different to normal control group.
  • the said experiment indicates: total alkaloids of Radix Stephaniae Epigaeae have significant reverse effect to TH increase and DAmRNA decrease after drug addiction withdrawal. It avoid excessive TH immunity positive reaction, decrease the inhibition of D 1 R mRNA and D 2 R mRNA gene expression in related brain area, and accelerate EOP, DA nervous system function naturally recover course in back brain after morphine addiction withdrawal. It gives a important basis for using the said invention medicine to treat opioids addiction.
  • Self-administration experimental apparatus rat self-administration experimental apparatus is invented by Beijing University drug dependence institute, and it include two big basic systems comprising a self-administration system and a control system.
  • the series of equipment are compose of industrial control computer, self-administration data collect and control system, special self-administration cage, constant speed infusion pump, intravenous infusion pipe system (including air filter, countercurrent prevent valve, shaft and so on), fluid road protect pipe, vest and so on.
  • saline control group rats Under environment inducing condition, when they returned to the cage (drug 5 addiction environment), saline control group rats completely without body withdrawal symptom recover intravenous self-administration behavior at that day. Compare with that, frequency and response number of rats, which are treated with the said pharmaceutical composition tablet for a month at convalescence stage, all reduced, and they relapse after average 8 days. However, after return to administration cage, treatment group rats, which take the said pharmaceutical composition tablet once per day, have inhibited intravenous self-administration behavior. It indicates that the said pharmaceutical composition preparation has intervention effect to intravenous self-administration relapse behavior of morphine addiction rats induced by environment.
  • testees take “6.26” drug abstinence capsule (this institute research a preparation containing opioid) for 4-7 days as drug abstinence treatment (all drug withdrawal), but there exists still a part of acute residual withdrawal symptom and slow protracted withdrawal symptom.
  • General condition and group condition of testees are showed as follows. Age, accumulated drug abuse time among 3 testee groups exist no statistics difference (P>0.05), but at drug abuse amount per day, admission body weight, there exists statistics difference because of sampling error factor (P ⁇ 0.05).
  • Administration method and dosage withdrawal symptom and not appear obvious poison response is a principle. Medications of two research groups are different, give compound group capsule, give single agent group same dosage of compound group's medication, give control group no medicine, give three groups one capsule each time, tid, administration for 10 days.
  • Assessment content according to research plan request, record truthfully: research medical record briefly; Withdrawal symptom observation assessment scale , Treatment emergent symptom scale (TESS) , HAMA anxious assessment scalez , Heroin protracted withdrawal symptom assessment scale , Urine morphine test (TLC); blood routine test, urine routine test; liver and renal function test.
  • TACS Treatment emergent symptom scale
  • HAMA anxious assessment scalez HAMA anxious assessment scalez
  • Heroin protracted withdrawal symptom assessment scale Urine morphine test (TLC); blood routine test, urine routine test; liver and renal function test.
  • Testees grade according to withdrawal symptom observation assessment scale and Treatment emergent symptom scale (TESS) at P.M. 7-8 in every day, determine and record blood pressure, pulse rate and body weight simultaneously. Assess by HAMA anxious assessment scale once per 5 days. Carry on urine morphine test, blood routine test, urine routine test at pre-admission and post-treatment respectively. All testees are managed with management pattern and regulation in forced drug addiction Rehabilitation. In treatment observation period, the testees participated in morning exercise, study, formation train, entertainment and labor as usual, without any special treatment compared with the other drug abstinents.
  • TESS withdrawal symptom observation assessment scale and Treatment emergent symptom scale
  • Admission standard stop use other drug abstinence medicines; almost eliminate the acute withdrawal symptom, but still leave certain degree withdrawal symptom.
  • Escape standard the testees whose urine morphine test is positive after treatment; the testees whose test results are abnormal or who cannot persist the treatment because of body disease after treatment beginning; the testees who escape treatment not because of treatment reason (for example criminal case); the testees refuse to take the medicine after invalid persuade.
  • Grades of two test groups have no bounce phenomenon for withdrawal symptom after drug withdrawal, they all decrease gradually day by day, and there is no significant different between two groups (P>0.05).
  • Adverse reaction grade of the said invention pharmaceutical composition compound is obviously lower than Radix Stephaniae Epigaeae single-agent, and there is significant different (P ⁇ 0.05).
  • Radix Stephaniae Epigaeae single-agent and the said invention pharmaceutical composition compound can both control acute residual withdrawal symptom after heroin dependence treatment, but its symptom control effect of the said invention pharmaceutical composition compound is better than effect of Radix Stephaniae Epigaeae single-agent; adverse reaction of compound is less than Radix Stephaniae Epigaeae single-agent, the compound has no obviously poisonous effect and side effect, and is safer and more reliable; the testees are rather accept to this medicine well, and also without dependence.
  • Starting material A Radix Ginseng 500 g, Rhizoma Corydalis 1600 g, Radix Astragali 2500 g, Radix Angelicae Sinensis 500 g, Radix Ophiopogonis 600 g; capsule 0.4 g/capsule, 2-3 capsules/time 3 times/day.
  • Starting material B Radix Ginseng 500 g, Radix Stephaniae Japonicae 1600 g, Radix Astragali 2500 g, Radix Angelicae Sinensis 500 g, Radix Ophiopogonis 600 g; capsule 0.4 g/capsule, 2-3 capsules/time 3 times/day.
  • Starting material C Radix Ginseng 500 g, Caulis Fibraureae 1600 g, Radix Astragali 2500 g, Radix Angelicae Sinensis 500 g, Radix Ophiopogonis 600 g; capsule 0.4 g/capsule, 2-3 capsules/time 3 times/day.
  • Starting material D Radix Ginseng 300 g, Radix Stephaniae Epigaeae 1600 g, Radix Astragali 1000 g, Radix Angelicae Sinensis 500 g, Radix Ophiopogonis 300 g; capsule 0.35 g/capsule, 2-3 capsules/time 3 times/day.
  • Starting material E total alkaloid of Radix Stephaniae Epigaeae (obtain by experiment 2). Tablet 0.35 g 2-3 tablets/time 3 times/day.
  • Placebo fill capsule with equal weight pharmaceutical starch: 2-3 capsules/time, 3 times/day. tid, administration 10 day.
  • Assessment index assess clinic assessment of new drug abstain medicine by clinic research assessment rule of new drug abstain medicine issued by State Drugs Administration.
  • Assessment index includes: Withdrawal symptom observation assessment scalez, 63 , z, 62
  • Treatment emergent symptom scale (TESS) HAMA anxious assessment scale at the same time, assess refer to Heroin protracted withdrawal symptom assessment scale of Chinese drug dependence institute.
  • Admission standard and escape standard stop use heroines narcotics and methadone, buprenorphine and so on of opioids drug abstinence medicines; almost eliminate the acute withdrawal symptom, but still leave certain degree withdrawal symptom.
  • Grade testees per day of each group during administration compare with control group, residual withdrawal symptom of each administration group was controlled or released, total grades decrease gradually without bounce phenomenon.
  • the curative effect order is group D, group E, group C, group B and group A, wherein withdrawal symptom total grade of group D decreases faster than other groups, and effect of group A is poor.
  • Adverse reaction grade of prescription group D and group E is obviously less than other groups after treatment.
  • curative effect of prescription group D is better than group E (total alkaloid of Radix Stephaniae Epigaeae)
  • group B Cumulis Fibraureae
  • group C Rostix Stephaniae Japonicae
  • Administration route administration by iv 0.5 mg/kg hydrochloric cocaine, fixation ratio 2 (namely obtain one injection by press staff twice).
  • iv 0.5 mg/kg hydrochloric cocaine, fixation ratio 2 (namely obtain one injection by press staff twice).
  • After establish self-administration model stochastically divide into 5 dosage group, observe once in every day, 3 hours every time, intraperitoneal injection total alkaloids of Radix Stephaniae Epigaeae 1, 3, 10, 20, 30 mg/kg at 30 minutes before every experiment. So 3-30 mg/kg can all inhibit cocaine intravenous self-administration dosage-dependence, and it indicates that total alkaloids of Radix Stephaniae Epigaeae have intervention function to psychic dependence and relapse behavior of cocaine addiction, show in FIG. 7 , FIG. 8 .
  • FIG. 1 is a chart depicting influence of total alkaloids of Radix Stephaniae Epigaeae for POMC mRNA gene expression in morphine dependence rat;
  • FIG. 2 is a record illustration depicting each index of the said invention pharmaceutical composition tablet about group A No. 1 rat experiment;
  • FIG. 3 is a record illustration depicting each index of the said invention pharmaceutical composition tablet about group B No. 2 rat experiment;
  • FIG. 4 is a mean graph depicting protracted withdrawal symptom after administration
  • FIG. 5 is a graph depicting mean change of withdrawal symptom per day
  • FIG. 6 is a graph depicting adverse reaction grade mean per day of two groups
  • FIG. 7 is a chart depicting dosage dependence relation change of cocaine addiction relapse behavior.
  • FIG. 8 is a chart depicting intervention to cocaine addiction relapse behavior.
  • THPBs tetrahydroprotoberberines
  • Extract according to example 1 method add general adjuvant, according to usual process, produce capsule, pack, that is.
  • Extract according to example 1 method add general adjuvant, according to usual process, produce granule, pack, that is.
  • Extract according to example 1 method add general adjuvant, according to usual process, produce oral liquid, pack, that is.
  • Identification include one of or several following methods:
  • the upper layer solution is a mixture of n-butyl alcohol, ethyl acetate and water (4:1:5), according to ratio 10:1, a mix solution of this upper layer solution and methanol is used as developer, in developing, the development chamber is saturated by ammonia for 30 minutes, and developed distance is more than 15 cm, the plate was removed and air dried, and sprayed with ethanol solution of 10% sulfuric acid, then heated in 105° C. until visualize the chromatogram, the chromatogram produced by the test sample solution showed the same color spots as that displayed by the two reference substance solutions in their respectively corresponding areas;
  • Tetrahydropalmatine regarded as Radix Stephaniae Epigaeae is not less than 20 mg in each of 0.35 g tablet of the said pharmaceutical composition.
  • Identification include one of or several following methods:
  • the upper layer solution is a mixture of n-butyl alcohol, ethyl acetate and water (4:1:5), according to ratio 10:1, a mix solution of this upper layer solution and methanol is used as developer, in developing, the development chamber is saturated by ammonia for 30 minutes, and developed distance is more than 15 cm, the plate was removed and air dried, and sprayed with ethanol solution of 10% sulfuric acid, then heated in 105° C. until visualize the chromatogram, the chromatogram produced by the test sample solution showed the same color spots as that displayed by the two reference substance solutions in their respectively corresponding areas;
  • the upper layer solution is a mixture of n-butyl alcohol, ethyl acetate and water (4:1:5), according to ratio 10:1, a mix solution of this upper layer solution and methanol is used as developer, in developing, the development chamber is saturated by ammonia for 30 minutes, and developed distance is more than 15 cm.
  • the plate was removed and air dried, and sprayed with ethanol solution of 10% sulfuric acid, then heated in 105° C. until visualize the chromatogram, the chromatogram produced by the test sample solution showed the same color spots as that displayed by the reference substance solution in its respectively corresponding area;
  • Tetrahydropalmatine regarded as Radix Stephaniae Epigaeae is not less than 20 mg in each of 0.45 g capsule of said pharmaceutical composition.
  • the upper layer solution is a mixture of n-butyl alcohol, ethyl acetate and water (4:1:5); according to ratio 10:1, a mix solution of this upper layer solution and methanol is used as developer.
  • the development chamber is saturated by ammonia for 30 minutes, and developed distance is more than 15 cm, the plate was removed and air dried, and sprayed with ethanol solution of 10% sulfuric acid, then heated in 105° C. until visualize the chromatogram, the chromatogram produced by the test sample solution showed the same color spots as that displayed by the two reference substance solutions in their respectively corresponding areas;
  • the upper layer solution is a mixture of n-butyl alcohol, ethyl acetate and water (4:1:5); according to ratio 10:1, a mix solution of this upper layer solution and methanol is used as developer, in developing, the development chamber is saturated by ammonia for 30 minutes, and developed distance is more than 15 cm, the plate was removed and air dried, and sprayed with ethanol solution of 10% sulfuric acid, then heated in 105° C. until visualize the chromatogram, the chromatogram produced by the test sample solution showed the same color spots as that displayed by the reference substance solution in its respectively corresponding area,
  • Tetrahydropalmatine regarded as Radix Stephaniae Epigaeae is not less than 20 mg in each of 0.4 g granule of the said pharmaceutical composition.
  • Pulverize Radix Stephaniae Epigaeae to coarse power add 5 times amount ethanol of stating material's, then extract by reflux extraction for two times, 2 hours each time, filter, combine the filtrates of ethanol extract, recover ethanol and concentrate to obtain the thick extract with relative density of 1.18-1.30 at 80° C.; acidify this thick extract until the pH value up to 2-3 by 5% HCl solution, filter, basify the filtrate until the pH value up to 9-10 by 10% NaOH solution, stand and collect the precipitate, wash the precipitate with water by filter, take the precipitate, dry it, then obtain total alkaloids from Radix Stephaniae Epigaeae, add general adjuvant, produce pill.
  • Pulverize Radix Stephaniae Epigaeae to 3 kg coarse power add 9 times amount 40% ethanol of stating material's, then extract by reflux extraction for four times, 1 hour each time, filter, combine the filtrates of ethanol extract, recover ethanol, then concentrate to obtain the thick extract with relative density of 1.18-1.30 at 80° C.; acidify this thick extract until the pH value up to 3 by 5% HCl solution, filter, basify the filtrate until the pH value up to 9 by 8-20% NaOH solution, stand, collect the precipitate, wash the precipitate with water by filter, take the precipitate, dry it, then obtain total alkaloids from Radix Stephaniae Epigaeae; add general adjuvant, produce injection.
  • Pulverize Radix Stephaniae Epigaeae to 3 kg coarse power add 8 times amount 50% ethanol of stating material's, then extract by reflux extraction for three times, 2 hours each time, filter, combine the filtrates of ethanol extract, recover ethanol, then concentrate to obtain the thick extract with relative density of 1.18-1.30 at 80° C.; acidify this thick extract until the pH value up to 2.5 by 12% HCl solution, filter, basify the filtrate until the pH value up to 9.5 by 15% NaOH solution, stand, collect the precipitate, wash the precipitate with water by filter, take the precipitate, dry it, then obtain total alkaloids from Radix Stephaniae Epigaeae; add general adjuvant, produce rapid-release preparation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US11/989,520 2005-07-26 2006-07-26 Medicine to Treat Drug Addiction and Preparation Method Thereof Abandoned US20090123559A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNA2005100855316A CN1726990A (zh) 2005-07-26 2005-07-26 含有效生物碱的天然中草药在戒毒药中的应用及提取工艺
CN200510085531.6 2005-07-26
PCT/CN2006/001856 WO2007012276A1 (fr) 2005-07-26 2006-07-26 Médicament destiné au sevrage de la dépendance aux drogues et procédé relatif à celui-ci

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2006/001856 A-371-Of-International WO2007012276A1 (fr) 2005-07-26 2006-07-26 Médicament destiné au sevrage de la dépendance aux drogues et procédé relatif à celui-ci

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/940,695 Division US8361524B2 (en) 2005-07-26 2010-11-05 Medicine to treat drug addiction and preparation method thereof

Publications (1)

Publication Number Publication Date
US20090123559A1 true US20090123559A1 (en) 2009-05-14

Family

ID=35926628

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/989,520 Abandoned US20090123559A1 (en) 2005-07-26 2006-07-26 Medicine to Treat Drug Addiction and Preparation Method Thereof
US12/940,695 Expired - Fee Related US8361524B2 (en) 2005-07-26 2010-11-05 Medicine to treat drug addiction and preparation method thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/940,695 Expired - Fee Related US8361524B2 (en) 2005-07-26 2010-11-05 Medicine to treat drug addiction and preparation method thereof

Country Status (7)

Country Link
US (2) US20090123559A1 (fr)
EP (1) EP1911456B1 (fr)
JP (2) JP2009502815A (fr)
CN (3) CN1726990A (fr)
AU (1) AU2006274356B2 (fr)
CA (1) CA2616328C (fr)
WO (1) WO2007012276A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113433244A (zh) * 2021-07-08 2021-09-24 辽宁华润本溪三药有限公司 气滞胃痛颗粒中延胡索乙素含量的测定方法及其应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102796096B (zh) * 2011-05-27 2016-09-14 中国科学院上海药物研究所 六氢二苯并[a,g]喹嗪类化合物、其制备方法、药物组合物及其应用
CN103083317B (zh) * 2013-01-14 2015-09-02 汉济生物科技（武汉）有限公司 一种复方药物及其配制方法
CN103284322B (zh) * 2013-04-02 2016-07-06 徐志强 一种能够抑制成瘾者对毒品渴求心瘾的香烟及其他制品及其制备方法
CN103543235B (zh) * 2013-11-08 2015-07-15 天津中医药大学 一种快速鉴别延胡索生熟饮片的方法
CN104042678B (zh) * 2014-06-13 2015-08-12 河南中医学院 一种治疗高脂血症的药物组合物及制备方法和用途
CN105403654B (zh) * 2015-12-11 2017-04-05 陇西保和堂药业有限责任公司 一种提高黄芪薄层色谱鉴定的方法
CN106176740B (zh) * 2016-07-01 2019-02-26 北京泰舟利泽医药科技有限公司 紫堇达明抗成瘾的医药用途
CN106074674A (zh) * 2016-08-29 2016-11-09 王彦春 一种黄芪饮片的加工方法
CN106511892B (zh) * 2016-11-21 2021-07-13 南京世纪博康医药科技有限公司 一种戒毒用中药组合物
CN109776635B (zh) * 2017-11-10 2021-08-17 北京以岭药业有限公司 一种中药组合物中八种成分的分离方法
CN108276400A (zh) * 2018-02-01 2018-07-13 重庆希尔安药业有限公司 一种左旋延胡索乙素的高产率提取方法
CN108264508A (zh) * 2018-02-01 2018-07-10 重庆希尔安药业有限公司 一种高纯度药用级罗通定原料的生产方法
US11236081B2 (en) * 2018-11-29 2022-02-01 Zheng Yang Crystalline salts of corydalmine
CN109316196B (zh) * 2018-12-12 2022-07-19 上海市精神卫生中心（上海市心理咨询培训中心） 基于虚拟现实联合脑电监测的苯丙胺类兴奋剂渴求评估方法
CN110133148A (zh) * 2019-05-30 2019-08-16 汉义生物科技（北京）有限公司 一种大麻hplc指纹图谱测定方法
CN110179889B (zh) * 2019-06-27 2021-07-02 遵义医学院附属医院 一种用于戒断海洛因毒瘾的中药组合物及其制备方法
CN111184719B (zh) * 2020-01-17 2023-02-28 上海交通大学 一种多巴胺受体拮抗剂及其用途
CN116392516B (zh) * 2023-04-14 2024-04-05 延边大学 一种人参提取物在制备膜剂中的应用、人参口腔膜剂及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2206407A (en) * 1938-06-28 1940-07-02 Kondo Heisaburo Method of preparing alkaloids from "tamasaki-tsuzurafuji" (stephania cepharantha, hayata) of the menispermaceae family
US6162437A (en) * 1997-11-25 2000-12-19 Korea Institute Of Science & Technology Method for inhibiting interleukin-6 production by administering extracts from root of Stephania tetrandra

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1174075A (zh) * 1997-07-12 1998-02-25 迟经惠 动脉硬化康
CN1174064A (zh) 1997-07-18 1998-02-25 迟经惠 湿疹药膏
US6218541B1 (en) * 1999-06-28 2001-04-17 Cba, International, Inc. Method for extracting bisbenzylisoquinolines
CN1219528C (zh) * 2002-02-23 2005-09-21 黄坤耀 一种治疗毒瘾的中成药
CN1738634B (zh) 2002-11-15 2010-11-03 汪建平 华千金藤的提取及使用方法
CN1537549A (zh) * 2003-04-15 2004-10-20 中国人民解放军军事医学科学院基础医 治疗兴奋剂戒断症状的中药复方制剂及其应用
CN1314408C (zh) * 2003-04-15 2007-05-09 中国人民解放军军事医学科学院基础医学研究所 治疗阿片类稽延性戒断症状的中药复方制剂及其应用
CN100540021C (zh) * 2004-05-19 2009-09-16 桂林三金药业股份有限公司 治疗结肠炎的中药组合物及其制备方法、质量控制方法
CN100579558C (zh) * 2004-09-23 2010-01-13 赤峰丹龙药业有限公司 一种治疗心脑血管疾病的颗粒剂的质量控制方法
CN100543469C (zh) * 2004-10-12 2009-09-23 江西江中药业股份有限公司 十全大补膏的检测方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2206407A (en) * 1938-06-28 1940-07-02 Kondo Heisaburo Method of preparing alkaloids from "tamasaki-tsuzurafuji" (stephania cepharantha, hayata) of the menispermaceae family
US6162437A (en) * 1997-11-25 2000-12-19 Korea Institute Of Science & Technology Method for inhibiting interleukin-6 production by administering extracts from root of Stephania tetrandra

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113433244A (zh) * 2021-07-08 2021-09-24 辽宁华润本溪三药有限公司 气滞胃痛颗粒中延胡索乙素含量的测定方法及其应用

Also Published As

Publication number Publication date
EP1911456B1 (fr) 2012-12-26
WO2007012276A1 (fr) 2007-02-01
CA2616328C (fr) 2015-12-15
US8361524B2 (en) 2013-01-29
CN1726990A (zh) 2006-02-01
CN101227917A (zh) 2008-07-23
US20110111074A1 (en) 2011-05-12
HK1118472A1 (en) 2009-02-13
EP1911456A4 (fr) 2012-05-02
CA2616328A1 (fr) 2007-02-01
EP1911456A1 (fr) 2008-04-16
CN102579791A (zh) 2012-07-18
AU2006274356B2 (en) 2010-11-04
JP2009502815A (ja) 2009-01-29
JP5770080B2 (ja) 2015-08-26
CN101227917B (zh) 2011-06-01
JP2012116838A (ja) 2012-06-21
CN102579791B (zh) 2013-11-20
AU2006274356A1 (en) 2007-02-01

Similar Documents

Publication Publication Date Title
US8361524B2 (en) Medicine to treat drug addiction and preparation method thereof
Bateman et al. Possible toxicity of herbal remedies
Huang The pharmacology of Chinese herbs
CN102416062A (zh) 枳实或枳实提取物的新用途
CN101496870B (zh) 一种止咳化痰的中药组合物的检测方法
CN102743401B (zh) 人参二醇皂苷组分在制备防治癫痫药物中的用途
CN101199683A (zh) 一种治疗皮肤病的中药及其制备方法
Adeyoju et al. Comparative in vivo antimalarial activities of aqueous and methanol extracts of MAMA powder-A herbal antimalarial preparation
CN101987124A (zh) 一种治疗消化不良中药组合物及其制备方法
Rosecrans et al. Pharmacological investigation of certain Valeriana officinalis L. extracts
CN108210600A (zh) 一种柠檬苦素类提取物的制备方法及其应用
CN101306132A (zh) 一种治疗抽动秽语综合征的药物组合物及其制备方法
CN1923263B (zh) 一种中药组合物及其制备方法和质量控制方法
CN107126469B (zh) 一种基于伴生原理制备的药物组合物及其在戒毒中应用
CN113069516A (zh) 一种防治皮肤瘙痒症的中药复方组合物及其用途
CN100563688C (zh) 一种戒毒止瘾中药组合物及其栓剂与应用
CN1857337B (zh) 败酱科植物及其提取物在制备治疗前列腺增生的药物中的用途
CN105853910A (zh) 一种具有神经保护作用的药物组合物及制备方法
CN104510781A (zh) 玄胡索的抗肿瘤疼痛用途
CN101450105B (zh) 一种当药制剂及其质量控制方法
HK1118472B (en) A medicine for abstaining from addiction to drugs and process thereof
CN100404047C (zh) 一种治疗痤疮湿疹的药物组合物及其制备方法
Mitra et al. Exploration of Antidiabetic and Diuretic Activities of Lumnitzera racemosa and Eclipta alba with Molecular Docking Study.
CN118384250A (zh) 清脑复神制剂在制备改善抑郁症药物中的应用
CN104547055A (zh) 元胡抗肿瘤晚期疼痛用途

Legal Events

Date Code Title Description
AS Assignment

Owner name: INSTITUTE OF BASIC MEDICAL SCIENCES, ACADEMY OF MI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YANG, ZHENG;FAN, MING;CHEN, JIJUN;AND OTHERS;REEL/FRAME:020649/0770

Effective date: 20080204

Owner name: SHANXI YABAO PHARMACEUTICAL GROUP CORP., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YANG, ZHENG;FAN, MING;CHEN, JIJUN;AND OTHERS;REEL/FRAME:020649/0770

Effective date: 20080204

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION